Hodgkin Lymphoma Transformation in CLL / SLL
April 14, 2025
Hodgkin lymphoma transformation is a rare type of Richter’s transformation in which CLL / SLL turns into Hodgkin lymphoma rather than DLBCL.
Hodgkin lymphoma transformation is a rare type of Richter’s transformation in which CLL / SLL turns into Hodgkin lymphoma rather than DLBCL.
As more and more drugs have become available to treat CLL, doctors and patients alike want to know what is the best way to sequence these therapies.
New novel agents are being tested in clinical trials to help patients with CLL who have developed resistance to all the BTK inhibitors and BCL2 inhibitors.
Epcoritamab, a bispecific antibody, shows encouraging early results in relapsed / refractory chronic lymphocytic leukemia (CLL) patients.
Richter’s transformation is a rare very aggressive complication of CLL. Learn the role of stem cell transplants in treating Richter’s transformation.
Richter’s transformation is a rare complication of CLL and changes in how clinical trials are conducted might help patients access novel therapies.
One year after Dr. Brian Koffman enrolled as the first chronic lymphocytic leukemia (CLL) patient in the epcoritamab clinical trial, all is well.
For patients with Richter’s transformation, the combination of ibrutinib, venetoclax, and obinutuzumab may be most useful as a bridge to other therapies.
CLL Society awarded Dr. Prajish Iyer a research grant for his project studying Richter’s transformation, a rare but aggressive progression of CLL.
© 2025 CLL Society. All Rights Reserved.
Legal | Privacy Policy | Corporate Giving Policy
Terms & Conditions | Report a Bug | Site Design
CLL Society Inc. is a patient–centric, physician–curated nonprofit organization focused on patient education, support, and research. Dedicated to addressing the unmet needs of the chronic lymphocytic leukemia (CLL) and related blood cancer communities, we explain the rapidly changing therapeutic landscape and the importance of clinical trials, support and build patient networks, engage in research, and educate providers and patients.
CLL Society is a registered 501(c)(3) tax-exempt nonprofit organization. All donations are tax-deductible to the greatest extent as allowed under federal law. CLL Society’s tax ID number is 46-4131354.
1454 Melrose Avenue, Ste. 1-247
Chula Vista, CA 91911